

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/072,430	PLATZ ET AL.	
	Examiner	Art Unit	
	Mina Haghighatian	1616	

All Participants:

(1) Mina Haghighatian.

(2) Mark A. Wilson.

Status of Application: _____

(3) _____.

(4) _____.

Date of Interview: 4 May 2004

Time: _____

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

All

Claims discussed:

All

Prior art documents discussed:

All


Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Examiner telephoned Mr. Wilson to discuss the scope of the instant claims with respect to prior art of record. More specifically, Mr. Wilson was advised that claims are interpreted in light of the specification, and since specification disclosed carbohydrates include cyclodextrin, the prior art citing formulations containing cyclodextrin appear to meet the limitations of the instant claims. Examiner suggested adding a negative limitation to independent claims 1 and 20 to more clearly distinguish them from prior art of record. The negative limitation was a recitation that cyclodextrin is not an ingredient of the formulation. Mr. Wilson agreed. Claims 14, 17 and 25 were also discussed. It was agreed upon that claim 14 be amended to depend from claim 1 and claims 17 and 25 be cancelled. .